Role of Retinoid Receptors in the Prevention and Treatment of Breast Cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 4, Issue 4, 1999, Pages 377-388

  Yang, LiMin ^a   Tin U, Caesar ^a   Wu, Kendall ^b   Brown, Powel ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Animal models; Breast cancer; Cancer prevention; Clinical trials; Retinoid receptor; Retinoids

Indexed keywords

GROWTH INHIBITOR; RETINOIC ACID RECEPTOR; RETINOID;

ANIMAL; BREAST TUMOR; CELL DIFFERENTIATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; GROWTH INHIBITORS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 0033202674     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018718401126     Document Type: Article

References (88)

1. R. C. Moon, R. G. Mehta, and K. V. N. Rao (1994). Retinoids and cancer in experimental animals. In M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids: Biology, Chemistry, and Medicine, Second Edition, Raven Press, New York, pp. 573-595.
2. M. E. Huang, Y. C. Ye, S. R. Chen, J. R. Chai, J. X. Lu, L. Zhao, L. J. Gu, and Z. Y. Wang (1988). Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567.
3. W. K. Hong, S. M. Lippman, L. M. Itri, D. D. Karp, J. S. Lee, R. M. Byers, S. P. Schantz, A. M. Kramer, R. Lotan, L. J. Peters, I. W. Dimery, B. W. Brown, and H. Goepfert (1990). Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323:795-801.
4. D. J. Mangelsdorf, K. Umesono, and R. Evans (1994). The retinoid receptors. In M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids: Biology, Chemistry, and Medicine, Second Edition, Raven Press, New York, pp. 319-349.
5. T. Perlmann and R. M. Evans (1997). Nuclear receptors in sicily: All in the famiglia. Cell 90:391-397.
6. R. J. Lin, L. Nagy, S. Inoue, W. Shao, W. H. Miller, Jr., and R. Evans (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-818.
7. S.-H. Hong, G. David, C.-W. Wong, A. Dejean, and M. L. Privalsky (1997). SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 94:9028-9033.
8. M. A. Pignatello, F. C. Kauffman, and A. A. Levin (1997). Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): Binding affinities and disposition. Toxicol Appl. Pharmacol. 142:319-327.
9. S. Toma, L. Isnaardi, L. Riccardi, and W. Bollag (1998). Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res. 18:935-942.
10. D. R. Shalinsky, E. D. Bischoff, W. W. Lamph, L. Zhang, M. F. Boehm, P. J. A. Davies, A. M. Nadzan, and R. A. Heyman (1997). A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res. 57:162-168.
11. J. Y. Chen, S. Penco, J. Ostrowski, P. Balague, M. Pon, J. Starrett, P. Reczek, P. Chambon, and H. Gronemeyer (1995). RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14:1187-1197.
12. S. Toma, L. Isnardi, P. Raffo, L. Riccaardi, G. Dastoli, C. Apfel, P. LeMotte, and W. Bollag (1998). RARα antagonist RO 41-5253 inhibits proliferation and induces apoptosis in breast cancer cell lines. Int. J. Cancer 78:86-94.
13. M. S. Sheikh, Z.-M. Shao, Z.-S. Li, J. V. Ordonez, B. A. Conley, S. Wu, M. I. Dawson, Q.-X. Han, W.-R. Chao, T. Quick, R. M. Niles, and J. A. Fontana (1995). N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16:2477-2486.
14. P. Kastner, M. Mark, and P. Chambon (1995). Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 83:859-869.
15. P. Kastner, J. M. Grondona, M. Mark, A. Gansmuller, M. LeMeur, D. Decimo, J.-L. Vonesch, P. Dolle, and P. Chambon (1994). Genetic analysis of RXRa developmental function: Concergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 78:987-1003.
16. V. Sapin, P. Dolle, C. Hindelang, P. Kastner, and P. Chambon (1997). Defects of the chorioallantoic placenta in mouse RXRα null fetuses. Dev. Biol. 191:29-41.
17. T. Manshouri, Y. Yang, H. Lin, S. A. Stass, A. B. Glassman, and M. J. Keating (1997). Downregulation of RARα in mice by antisense transgene leads to a compensatory increase in RARβ and RARγ and development of lymphoma. Blood 89:2507-2515.
18. P. Kastner, M. Mark, M. Leid, A. Gansmuller, J. M. Grondona, D. Decimo, W. Krezel, B. Chin, A. Dierich, and P. Chambon (1996). Abnormal spermatogenesis in RXRβ mutant mice. Genes Dev. 10:80-92.
19. -/- mutant mice are viable. Proc. Natl. Acad. Sci. USA 93:9010-9014.
20. R. C. Moon, R. G. Mehta, and D. L. McCormick (1985). Retinoids and mammary gland differentiation. In Retinoids, Differentiation and Disease, Pittman, London, pp. 156-167.
21. L. J. Gudas (1992). Retinoids, retinoid-response genes, cell differentiation and cancer. Cell Growth Differ. 3:655-662.
22. S. D. Roman, C. L. Clarke, R. E. Hall, I. E. Alexander, and R. L. Sutherland (1992). Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res. 52:2236-2242.
23. K. Swisshelm, K. Ryan, X. Lee, H. C. Tsou, M. Peacock, and R. Sager (1994). Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5:133-141.
24. X.-C. Xu, N. Sneige, X. Liu, R. Nandagiri, J. J. Lee, F. Lukmanji, G. Hortobagyi, S. M. Lippman, K. Dhingra, and R. Lotan (1997). Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res. 57:4992-4996.
25. B. van der Burg, B. M. van der Leede, L. Kwakkenbos-Isbrucker, S. Salverda, S. W. de Laat, and P. T. van der Saag (1993). Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol. Cell Endocrinol. 91:149-157.
26. P. Fitzgerald, M. Teng, R. A. S. Chandraratna, R. A. Heyman, and E. A. Allegretto (1997). Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res. 57:2642-2650.
27. M. S. Sheikh, Z.-M. Shao, X.-S. Li, M. Dawson, A. M. Jetten, S. Wu, B. A. Conley, M. Garcia, H. Rochefor, and J. A. Fontana (1994). Retinoid-resistant estrogen receptor-negative human breast carcimoma cells transfected with retinoic acid receptor-α acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. 269:21440-21447.
28. T. K. Chen, L. M. Smith, D. K. Gebhardt, M. J. Birrer, and P. H. Brown (1996). Activation and inhibition of the AP1 complex in human breast cancer cells. Mol. Carcinogenesis 15:215-226.
29. L. M. Smith, M. J. Birrer, M. R. Stampfer, and P. H. Brown (1997). Breast cancer cells have lower mammalian activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 57:3046-3054.
30. M. Pfahl (1993). Nuclear receptor/AP-1 interaction. Endocrine Rev. 14:651-658.
31. L. Yang, H.-T. Kim, D. Munoz-Medellin, P. Reddy, and P. H. Brown (1997). Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res. 57:4652-4661.
32. S. Kojima and D. B. Rifkin (1993). Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells. J. Cell Physiol. 155:323-332.
33. J. Nunes, S. Kojima, and D. B. Rifkin (1996). Effect of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid-treated HL-60 cells. Cancer Res. 56:495-499.
34. K. M. Eck, L. Yuan, L. Duffy, and P. T. Ram (1998). A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumor cells. Brit. J. Cancer 77:2129-2137.
35. J. M. Turley, L. A. Falk, F. W. Ruscetti, J. J. Kasper, T. Francomano, T. Fu, O. S. Bang, and M. C. Birchenall-Roberts (1996). Transforming growth factor β1 functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Differ. 7:1535-1544.
36. M. Hosobuchi and M. R. Stampfer (1989). Effects of transforming growth factor β- on growth of human mammary epithelial cells in culture. In Vitro Cell Dev. Biol. 25:705-713.
37. V. L. Seewaldt, J.-H. Kim, L. E. Caldwell, B. S. Johnson, K. Swisshem, and S. J. Collins (1997). All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ. 8:631-641.
38. J. L. Martin, J. A. Coverley, S. T. Pattison, and R. C. Baxter (1995). Insulin-like growth factor binding protein-3 production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136:1219-1226.
39. Y. Oh, Z. Gucev, L. Ng, H. L. Muller, and R. G. Rosenfeld (1995). Antiproliferaative actions of insulin-like growth factor binding protein (IGFBP-3) in human breast cancer cells. Prog. Growth Factor Res. 6:503-512.
40. Z. S. Gucev, T. Y. O, K. M. Kelley, and R. G. Rosenfeld (1996). Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res. 56:1545-1550.
41. V. L. Seewaldt, B. S. Johnson, M. B. Parker, S. J. Collins, and K. Swisshelm (1995). Expression of retinoic acid receptor β mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 6:1077-1088.
42. H. DeThe, M. del Mar Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean (1990). Identification of a retinoic acid responsive element in the retinoic acid receptor-β gene. Nature 343:177-180.
43. X.-S. Li, Z.-M. Shao, M. S. Sheikh, J. L. Eiseman, D. Sentz, A. M. Jetten, J.-C. Chen, M. I. Dawson, S. Aisner, A. K. Rishi, P. Gutierrez, L. Schnapper, and J. A. Fontana (1995). Retinoic acid nuclear receptor β inhibits breast carcinoma anchorage independent growth. J. Cell. Physiol. 165:449-458.
44. Q. Zhou, M. Stetler-Stevenson, and P. S. Steeg (1997). Inhibitions of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15:107-115.
45. S. Toma, L. Isnardi, P. Raffo, G. Dastoli, E. DeFrancisci, L. Riccardi, R. Palumbo, and W. Bollag (1997). Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast cancer cell lines: Growth inhibition and apoptosis induction. Int. J. Cancer 70:619-627.
46. A. N. Fanjul, F. J. Piedrafita, H. Al-Shamma, and M. Pfahl (1998). Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res. 58:4607-4610.
47. Y. Jing, J. Zhang, S. Waxman, and R. Mira-y-Lopez (1996). Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 60:109-117.
48. P. T. Lee, M. T. Lee, K. M. Darcy, K. Shudo, and M. M. Ip (1995). Modulation of normal mammary epithelial cell proliferation, morphogenesis, and functional differentiation by retinoids: A comparison of the retinobenzoic acid derivative RE80 with retinoic acid. Endocrinology 136: 1707-1717.
49. Y. S. Lopez-Boado, J. Tolivia, and C. Lopez-Otin (1994). Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells. J. Biol. Chem. 269:26871-26878.
50. S. S. Bacus, K. Kiguchi, D. Chin, C. R. King, and E. Huberman (1990). Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinogenesis 3:350-362.
51. R. Clarke (1996). Animal models of breast cancer. In J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast, Lippincott-Raven, pp. 235-244.
52. R. Clarke (1997). Animal models of breast cancer: Experimental design and their use in nutritin and psychosocial research. Breast Cancer Res. Treat. 46:117-133.
53. C. J. Grubbs et al. (1991). Effect of canthaxanthin on chemically induced mammary carcinogenesis. Oncology 48:239-245.
54. R. C. Moon, H. J. Thompson, P. J. Becci, C. J. Grubbs, R. J. Gander, D. L. Newton, J. M. Smith, S. L. Phillips, W. R. Henderson, L. T. Mullen, C. C. Brown, and M. B. Sporn (1979). N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39:1339-1346.
55. H. Abou-Issa, T. E. Webb, J. P. Minton, and M. Moeschberger (1989). Chemotherapeautic evaluation of glucarate and N-(4-hydroxyphenyl)retinamide alone and in combination in the rat mammary tumor model. J. Natl. Cancer. Inst. 81:1820-1823.
56. C. J. Grubbs, I. Eto, M. M. Juliana, J. M. Hardin, and L. M. Whitaker (1990). Effects of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumors. Anticancer Res. 10:661-666.
57. R. C. Moon, D. L. McCormick, and R. G. Methta (1983). Inhibition of carcinogenesis by retinoids. Cancer Res. 43:2469-2475s.
58. M. A. Anzano, S. W. Byers, J. M. Smith, C. W. Peer, L. T. Mullen, C. C. Brown, A. B. Roberts, and M. B. Sporn (1994). Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:4614-4617.
59. M. A. Anzano, C. W. Peer, J. M. Smith, L. T. Mullen, M. W. Shrader, D. L. Logsdon, C. L. Driver, C. C. Brown, A. B. Roberts, and M. B. Sporn (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Instit. 88:123.
60. M. M. Gottardis, E. D. Bischoff, M. A. Shirley, M. A. Wagoner, W. W. Lamph, and R. A. Heyman (1996). Chemopreventio n of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand. Cancer Res. 56:5566-5570.
61. E. D. Bischoff, M. M. Gottardis, T. E. Moon, R. A. Heyman, and W. W. Lamph (1998). Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 58:479-484.
62. E. Elstner, C. Muller, K. Koshizuka, E. A. Williamson, D. Park, H. Asou, P. Shintaku, J. W. Said, D. Heber, and H. P. Koeffler (1998). Ligands for peroxisome proliferaor-activated receptor γ and retinoic acid receptor inhibit growth and induce apaptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A. 95:8806-8811.
63. B. A. Conley, T. S. Ramsland, D. L. Sentz, S. Wu, D. M. Rosen, M. Wollman, and J. L. Eiseman (1999). Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother. Pharmacol. 43:183-197.
64. L. D. Fraker, S. A. Halter, and J. T. Forbes (1984). Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res. 44:5757-5763.
65. S. A. Halter, L. D. Fraker, D. Adcock, and S. Vick (1988). Effect of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice. Cancer Res. 48:3733-3736.
66. R. R. Mehta, M. E. Hawthorne, J. M. Graves, and R. G. Mehta (1998). Metabolism of N-[4-hydroxyphenyl ]retinamide (4-HPR) to N-[4-methoxyphenyl ]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur. J. Cancer 34:902-907.
67. C. Watson, D. Medina, and J. H. Clark (1977). Estrogen receptor characterization in transplantable mouse mammary tumor. Cancer Res. 37:3344-3348.
68. F. Darro, P. Cahen, A. Vianna, C. Decaestecker, J. M. Nogaret, B. Leblond et al. (1998). Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 antiprogestagen. Breast Cancer Res. Treat. 51:39-55.
69. G. N. Rao, E. Ney, and R. A. Herbert (1998). Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res. Treat. 48:265-271.
70. I. G. Maroulakou, M. Anver, L. Garrett, and J. E. Green (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. U.S.A. 91:11236-11240.
71. J. S. Lee, R. A. Newman, S. M. Lippman, M. H. Huber, T. Minor, M. N. Raber, I. H. Krakoff, and W. K. Hong (1993). Phase I Evaluation of all-trans-retinoic acid in adults with solid tumors. J. Clinical Oncol. 11:959-966.
72. L. M. Sutton, M. A. Warmith, W. P. Petros, and E. P. Winer (1997). Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast canceer: A phase II trial. Cancer Chemother. Pharmacol. 40:335-341.
73. J. Cassidy, M. Liffman, A. Lacroix, and G. Peck (1982). Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 18:925-928.
74. V. A. Miller, J. R. Rigas, F. M. Benedetti, A. L. Verret, W. P. Tong, M. G. Kris, G. M. Gill, G. R. Loewen, J. A. Truglia, E. H. Ulm, and R. P. Warrell, Jr., (1996). Initial clinical trial of the retinoid receptor pan agonist 9-cis-retinoic acid. Clinical Cancer Res. 2:471-475.
75. A. Costa, W. Malone, M. Perloff, F. Buranelli, T. Campa, G. Dossena, A. Magni, M. Pizzichetta, C. Andreoli, M. Del Vecchio, et al. (1989). Tolerability of the synthetic retinoid Fenretinide (HPR). Eur. J. Cancer Clin. Oncol. 25:805-808.
76. M. R. Modiano, W. S. Dalton, S. M. Lippman, L. Joffe, A. R. Booth, and F. L. Meyskens, Jr. (1990). Phase II study of fenretinide (N-[4-hydroxyphenyl ]retinamide) in advanced breast cancer and melanoma. Invest. New Drugs 8:317-319.
77. V. A. Miller, F. M. Benedetti, J. R. Rigas, A. L. Verret, D. G. Pfister, D. Straus, M. G. Kris, M. Crisp, R. Heyman, G. R. Loewen, J. A. Truglia, and R. P. Warrell, Jr., (1997). Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J. Clinical Oncol. 15:790-795.
78. M. A. Cobleigh, K. Dowlatshihi, T. A. Deutsch, R. G. Mehta, R. C. Moon, F. Minn, A. B. Benson, III, A. W. Rademaker, J. B. Ashenhurst, J. L. Wade, III and J. Wolter (1993). Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J. Clinical Oncol. 11:474-477.
79. G. T. Budd, P. C. Adamson, M. Gupta, P. Homayoun, S. K. Sandstrom, R. F. Murphy, D. McLain, L. Tuason, D. Peereboom, R. M. Bukowski, and R. Ganapathi (1998). Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clinical Cancer Res. 4:635-642.
80. F. Recchia, S. Rea, G. Corrao, A. Fingerhut, and L. Frati (1995). Sequential chemotherapy, β interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. A pilot study. Eur. J. Cancer 31A:1887-1888.
81. F. Recchia, G. Sica, S. DeFilippis, S. Discepoli, S. Rea, P. Torchio, and L. Frati (1995). Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer: A phase II study. J. Interferon Cytokine Res. 15:605-610.
82. A. Costa, F. Formelli, F. Chiesa, A. Decensi, G. DePalo, and U. Veronesi (1994). Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54:2032s-2037s.
83. U. Veronesi, G. DePalo, A. Costa, F. Formelli, E. Marubini, and M. DelVecchio (1992). Chemoprevention of breast cancer with retinoids. J. Natl. Cancer Institute Monographs 12:93-97.
84. G. De Palo, T. Camerini, E. Marubini, A. Costa, F. Formelli, M. DelVechio, L. Mariani, R. Miceli, G. Mascotti, A. Magni, T. Campa, M. G. DiMauro, A. Attili, C. Maltoni, M. R. Del-Turco, A. Decensi, G. D'Aiuto, and U. Veronessi (1997). Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83:884-894.
85. A. Costa, G. DePalo, A. Decensi, F. Formelli, F. Chiesa, M. Nava, T. Camerini, E. Marubini, and U. Veronesi (1995). Retinoids in cancer chemoprevention, clinical trials with the synthetic analogue fenretinide. Ann. N. Y. Acad. Sci. 768:148-162.
86. A. Costa, B. Boonanni, L. Manetti, A. G. Gonzaga, R. Torrisi, and A. Decensi (1998). Prevention of breast cancer: Focus on chemoprevention. Recent Results Cancer Res. 152:11-21.
87. G. De Palo, U. Veronesi, T. Camerini, F. Formelli, G. Mascoti, C. Boni, V. Fosser, M. DelVecchio, T. Campa, A. Costa, and E. Marubini (1995). Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Instit. 87:146-147.
88. L. M. Yang, D. Munoz-Medellin, H. T. Kim, J. Ostrowski, P. Reczek, and P. H. Brown (1999). Retinoic acid receptor antagonist BMS 453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res. and Treat. 56:277-291.